October 18, 2023 11:15 AM EDT

Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M

Jaimy Lee

Deputy Editor

Ligand acquires partial royalty rights to epilepsy candidate: Ligand said Wednesday that it’s paying $30 million upfront to Ovid Therapeutics as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Lig­and pays $30M up­front in roy­al­ty deal; Ac­tym ex­tends its Se­ries A; Gero rais­es $6M

Deputy Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M